Meeting
2016 ASCO Annual Meeting
Comparison of endoxifen levels between male and female breast cancer patients treated with tamoxifen.
Authors
John Gordon Lenehan
London Regional Cancer Centre, London, ON, Canada
John Gordon Lenehan , Wendy A. Teft , Richard B. Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 34, 2016 (suppl; abstr 578)
DOI
10.1200/JCO.2016.34.15_suppl.578
Abstract #
578
Poster Bd #
66
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Impact of curcumin with and without (+/-) piperine on tamoxifen exposure.
First Author: Gerardus Hussaarts
Poster
2016 ASCO Annual Meeting
Simplified CYP2D6 metabolizer phenotype categorization of patients treated with tamoxifen: Role for endoxifen level monitoring?
First Author: Clara Inkyung Lee
Poster
2012 ASCO Annual Meeting
CYP2D6 genotype and adverse effects as indicators of plasma endoxifen in breast cancer patients taking tamoxifen.
First Author: Bavanthi Balakrishnar
Poster
2020 ASCO Virtual Scientific Program
Relationship between CYP2D6 genotype, tamoxifen metabolites, and adverse events, tumor biomarkers and breast cancer recurrence in a low-dose phase III trial in noninvasive disease.
First Author: Andrea De Censi